Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
Fiche publication
Date publication
janvier 2024
Journal
NEJM evidence
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Fizazi K, Bernard-Tessier A, Roubaud G, Utriainen T, Barthélémy P, Fléchon A, van der Voet J, Gravis G, Ratta R, Jones R, Parikh O, Tanner M, Antonarakis ES, Baldini C, Peters N, Garratt C, Ikonen T, Pohjanjousi P, Joensuu H, Cook N
Lien Pubmed
Résumé
Targeted Inhibition of CYP11A1 in Prostate CancerIn this single-arm, multicenter, combined phase 1 and phase 2 study, patients with metastatic prostate adenocarcinoma with progression on prior androgen receptor pathway inhibitors and taxane-based chemotherapy were treated with ODM-208. A decrease in prostate-specific antigen levels of 50% or more occurred in 16/42 (38.1%) and 24/45 (53.3%) in phase 1 and 2 respectively. Responses mainly occurred in patients with androgen receptor mutations. Adrenal insufficiency was the dose-limiting toxicity.
Mots clés
Male, Humans, Receptors, Androgen, therapeutic use, Prostatic Neoplasms, Castration-Resistant, drug therapy, Cholesterol Side-Chain Cleavage Enzyme, Prostate-Specific Antigen, therapeutic use, Treatment Outcome, Androgen Receptor Antagonists, pharmacology
Référence
NEJM Evid. 2024 01;3(1):EVIDoa2300171